Identification of immunological predictors of COVID-19 clinical outcomes

NIH Pandemic-Era Grants

Pandemic Era Grants

2024

↗ Live URL (may be dead)

Document text

Principal Investigator: Andrea  Lisco
Organization: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Fiscal Year: 2024
Award: $71,700
Funding agency: National Institute of Allergy and Infectious Diseases

The extraordinarily wide spectrum of clinical manifestations associated with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, ranging from completely asymptomatic to fatal disease, represents an unexpected and yet unexplained clinical feature for an emerging highly contagious novel human pathogen. The study of the innate or adaptive response to SARS-Cov2 in immunocompetent and immunocompromised hosts can help deciphering the immunological predictors associated with the  such clinical outcomes as well as the immune response to immunizations.
In FY24, leveraging a collaboration with a network of Italian medical centers and NIAID investigators we have identified novel predictors of the breadth and longevity of T cell-response as well as the immune responses to mRNA SARS-CoV2 vaccines.

Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><COVID disease severity><COVID severity><COVID-19><COVID-19 disease severity><COVID-19 infection><COVID-19 severity><COVID-19 vaccine><COVID-19 virus><COVID-19 virus infection><COVID19 disease severity><COVID19 infection><COVID19 severity><COVID19 virus><CV-19><Clinical><CoV-2><CoV2><Collaborations><Coronavirus Infectious Disease 2019><Disease><Disorder><Goals><Immune response><Immunization><Immunochemical Immunologic><Immunocompetent><Immunocompromised><Immunocompromised Host><Immunocompromised Patient><Immunologic><Immunological><Immunological response><Immunologically><Immunologics><Immunosuppressed Host><Individual><Investigators><Length of Life><Longevity><Medical center><Messenger RNA><NIAID><National Institute of Allergy and Infectious Disease><Outcome><Research Personnel><Researchers><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 disease severity><SARS-CoV-2 infection><SARS-CoV-2 severity><SARS-CoV-2 vaccine><SARS-CoV2><SARS-CoV2 infection><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><T cell response><Wuhan coronavirus><clinical predictors><coronavirus disease 2019><coronavirus disease 2019 disease severity><coronavirus disease 2019 infection><coronavirus disease 2019 severity><coronavirus disease 2019 vaccine><coronavirus disease 2019 virus><coronavirus disease severity><coronavirus disease-19><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus infectious disease-19><hCoV19><host response><human pathogen><immune competent><immune system response><immunoresponse><immunosuppressed patient><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><mRNA><nCoV vaccine><nCoV-19 vaccine><nCoV19 vaccine><nCoV2><novel><response><severe acute respiratory syndrome coronavirus 2 disease severity><severe acute respiratory syndrome coronavirus 2 severity><vaccine against 2019-nCov><vaccine against COVID-19><vaccine against SARS-CoV-2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine candidates against SARS-CoV-2><vaccine for novel coronavirus><vaccines preventing COVID><vaccines to prevent COVID>